Divisions emerge over House drug price bills

Divisions emerge over House drug price bills
© Getty Images

Divisions are emerging in the House over what lawmakers hoped would be a bipartisan push to lower drug prices.

Drug pricing is a rare area where members of both parties think there is a chance for a deal this year. But as House Democrats took the first step on Wednesday to begin moving legislation forward, it was clear that even relatively small-scale drug pricing bills may not have a smooth path ahead.

ADVERTISEMENT

Republicans on the House Energy and Commerce Committee raised objections to several of the bills at the hearing, accusing Democrats of refusing to negotiate with them on the legislation.

“We do want to lower the cost of prescription drugs, [but] we wish it were more inclusive,” said Rep. Greg WaldenGregory (Greg) Paul WaldenHere are the eight Republicans who voted with Democrats on the Equality Act House approves anti-LGBT discrimination Equality Act Overnight Health Care — Presented by Campaign for Accountability — House passes drug pricing bills amid ObamaCare row | Senate Republicans running away from Alabama abortion law | Ocasio-Cortez confronts CEO over K drug price tag MORE (Ore.), the top Republican on the committee, about the process.

Democrats pointed out that many of the bills, which are aimed at increasing competition from cheaper generic drugs, already have support from some Republican lawmakers.

The bills are likely to pass the Democratic-controlled House. But getting a significant number of House Republicans on board for a strong vote would raise pressure on the GOP-controlled Senate to act on the issue.

Some Democrats are also hoping that winning support from President TrumpDonald John TrumpTrump: 'I will not let Iran have nuclear weapons' Rocket attack hits Baghdad's Green Zone amid escalating tensions: reports Buttigieg on Trump tweets: 'I don't care' MORE, who has railed against the high cost of drugs, will help win over more congressional Republicans.

Speaker Nancy PelosiNancy Patricia D'Alesandro PelosiPelosi receives John F. Kennedy Profile in Courage Award Dems walk Trump trade tightrope Tlaib calls on Amash to join impeachment resolution MORE (D-Calif.) said last week that Trump “assured” her that he wants to work together on lowering drug prices.

But without the support of GOP congressional leaders, passing the bill with strong Republican support becomes a much harder task.

ADVERTISEMENT
The relatively small-scale measures considered Wednesday, many of which have at least some bipartisan support, are part of a House Democratic strategy to start with “low-hanging fruit” on drug prices before later moving on to bigger items like Medicare negotiating drug prices.

But even the low-hanging fruit is exposing divisions.

House Energy and Commerce Committee Chairman Frank Pallone Jr.Frank Joseph PalloneThe Hill's Morning Report - Presented by Pass USMCA Coalition - Restrictive state abortion laws ignite fiery 2020 debate Work on surprise medical bills goes into overdrive Overnight Health Care — Presented by Campaign for Accountability — Alabama bill heats up fight over abortion | 2020 Dems blast bill | ACLU challenges Ohio abortion law | NC sues e-cig maker Juul | Flurry of activity on surprise medical bills MORE (D-N.J.) said the measures considered Wednesday would increase competition in the marketplace from cheaper generic drugs. He tried to frame the issue with language that could appeal to GOP lawmakers.

“This is capitalism,” Pallone said. “That’s what we’re about here.”

Asked after the hearing whether there is a path forward for him to support the measures, Walden said “possibly” but noted that he wanted changes.

“I guess the question is the next step and whether the majority’s willing to make some improvements,” Walden told The Hill.

Those concerns were also amplified on Tuesday by Rep. Michael BurgessMichael Clifton BurgessBipartisan House panel leaders ask agencies for maternal mortality data Overnight Health Care — Presented by PCMA — Sanders to roll out 'Medicare for all' bill | Dems target Juul over Altria ties | Measles cases spike nationwide GOP rep who supports lowering voting age: 'It's on us' if 16-year-olds vote Democratic MORE (R-Texas), the ranking member of the House Energy and Commerce Subcommittee on Health.

Burgess told The Hill that Democrats only shared the drug bills with him last week instead of bringing him in for negotiations.

“It could have been much better handled,” he said.

One of the highest-profile measures before the committee on Wednesday was the Creates Act. The bill would crack down on drug companies who game the system to delay competition from generic drugs.

Democrats noted that the bill already has Republican supporters, including Reps. David McKinleyDavid Bennett McKinleyThirty-four GOP members buck Trump on disaster bill Divisions emerge over House drug price bills Key Republican says Dems left him out of process on drug pricing bills MORE (W.Va.), Doug CollinsDouglas (Doug) Allen CollinsProsecutor appointed by Barr poised to enter Washington firestorm The CASE Act is an opportunity for creators to have rights and remedies GOP lawmaker: Mueller should 'come to Congress' MORE (Ga.) and Mark MeadowsMark Randall MeadowsThe Hill's Morning Report - Presented by Pass USMCA Coalition - After GOP infighting, Trump Jr. agrees to testify again On The Money: House chairman issues subpoenas for Trump's tax returns | Trump touts trade talks as China, US fail to reach deal | Five things to know about Trump's trade war with China | GOP offers support for Trump on tariffs GOP offers support for Trump on China tariffs MORE (N.C.), the chairman of the conservative House Freedom Caucus.

In the Senate, Sen. Chuck GrassleyCharles (Chuck) Ernest GrassleyOvernight Defense: Trump rails against media coverage | Calls reporting on Iran tensions 'highly inaccurate' | GOP senator blocking Trump pick for Turkey ambassador | Defense bill markup next week Trump reaches deal to lift steel, aluminum tariffs on Mexico, Canada Top GOP senator blocking Trump's pick for Turkey ambassador MORE (R-Iowa), the chairman of the Finance Committee, also supports the measure.

“We actually have some diversity of opinion on our side,” Walden acknowledged, before joking, “and you should see it on some other topics.”

House Republicans at the hearing, though, raised concerns that the measures could harm innovation from drug companies or set off “frivolous lawsuits” from generic drug companies.

Rep. Fred UptonFrederick (Fred) Stephen UptonThirty-four GOP members buck Trump on disaster bill Overnight Health Care: Lawmakers get deal to advance long-stalled drug pricing bill | House votes to condemn Trump's anti-ObamaCare push | Eight House Republicans join with Dems | Trump officials approve Medicaid expansion in Maine The 8 Republicans who voted against Trump's anti-ObamaCare push MORE (R-Mich.), a former chairman of the committee, warned of the “unintended consequences of hampering innovation in medicine.”

The brand-name drug industry, a powerful force in Washington, has raised similar concerns and has long worked against many of the bills Democrats brought up for consideration Wednesday. 

Democrats pushed back on the criticism.

Rep. Anna EshooAnna Georges EshooHillicon Valley: Court rejects Chelsea Manning appeal | Facebook hires lawyer who helped write Patriot Act | Senator seeks details on Russian interference in Florida | Amazon hiring alcohol lobbyist | Ex-Obama aide lobbying for Sprint, T-Mobile merger Former Obama aide lobbying for T-Mobile-Sprint merger T-Mobile merger poses more questions than answers MORE (D-Calif.), the chairwoman of the Health Subcommittee, said “the sky is really not caving in” and noted that GOP lawmakers already support some of the bills.

But Republicans were insistent they wanted changes to the bill highlighting the complicated debate over drug prices.

Rep. Peter WelchPeter Francis WelchBernie Sanders is hypocritical on most significant campaign issues Booker takes early lead in 2020 endorsements Divisions emerge over House drug price bills MORE (D-Vt.), one of the House’s fiercest critics of drug companies, expressed hope that a deal could be reached.

At a separate hearing on Tuesday, Welch secured commitments from Health and Human Services Secretary Alex Azar to work with lawmakers on bills, including the Creates Act.

“It’s kind of exciting to be here because we’re actually on the threshold of doing something,” Welch said.